

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**WO 99/06831**(51) International Patent Classification <sup>6</sup> :  
**G01N 33/53****A2**

(11) International Publication Number:

(43) International Publication Date: 11 February 1999 (11.02.99)

(21) International Application Number: **PCT/EP98/04754**

(22) International Filing Date: 29 July 1998 (29.07.98)

(30) Priority Data: 60/054,101 29 July 1997 (29.07.97) **US**(71)(72) Applicant and Inventor: DORSSEERS, Lambert, C., J.  
(NL/NL); Dept. of Pathology, MolBiol, Josephine Nefkens  
Institute, Erasmus University Rotterdam, Be 432, P.O. Box  
1738, NL-3000 DR Rotterdam (NL).(74) Agents: BRASNETT, Adrian, H. et al.; Mewburn Ellis, York  
House, 23 Kingsway, London WC2B 6HP (GB).(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,  
GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,  
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO  
patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,  
IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**Published***Without international search report and to be republished  
upon receipt of that report.*(54) Title: **BREAST CANCER RESISTANCE GENES, METHODS FOR THEIR DETECTION AND USES THEREOF**

(57) Abstract

The present invention relates to the finding of genes associated with the development of estrogen independent malignant cell growth, particularly of breast cancer cells. The invention provides assay methods for the diagnosis or prognosis of malignant cell growth, which method comprises measuring the expression of one or more of the *BCAR1*, *BCAR2* or *BCAR3* genes in a biological sample from a patient. Measurement may be by immunological techniques or by hybridisation with nucleic acids, utilising novel sequences and antibodies of the invention.